Crystal Mesh: The inside story of how women’s health was traded for quick cash Get The Book

(800) 511-3838 |

Early Indicators of Kidney Failure

  • Abnormal protein levels in urine
  • High creatinine levels
  • Abnormal GFR
  • Acute Kidney Injury
  • Low Kidney Function

Diagnoses: Kidney Disease, Chronic Kidney Disease, Fanconi Syndrome, Kidney Failure

Early Indicators of Bone Loss

  • Bone Density Loss
  • Bone Demineralization
  • Bone Weakening
  • Bone Fracture
  • Tooth Loss

Diagnoses: Osteopenia, Osteoporosis, Osteomalacia

What They Knew

Gilead knew that TAF was superior to TDF in both safety and superiority.  Their patent application showed that TAF produced a 10 fold increase in antiviral activity compared to TDF. Gilead knew it had a better option all along and deliberately selected against that option. Profit motivated their decision not to bring TAF to the market since their TDF patent meant big dollars.

When They Knew It

In 2000, knowing they had a superior, safer alternative to TDF in TAF, they patented TDF.  In 2001, Viread, the first TDF medication went on the market. From 2004-2012, Gilead strung out their patent and released four more TDF drugs, all while knowing TAF was safer and more effective. In July 16, 2012, the FDA approved Truvada® (F/TDF) for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually-acquired HIV-1 infection in at-risk adults. 

What You Can Do

If you or a loved one have been diagnosed with HIV and have taken Viread, Truvada, Atripla, Complera, Stribild or Truvada for PrEP and have subsequently been diagnosed with kidney disease, chronic kidney disease, Fanconi Syndrome, Kidney Failure, Osteopenia, Osteoporosis, or Osteomalacia, contact us today to see if you qualify to make a claim.

Truvada Warnings In The News

BREAKING (11/7/19): Trump Administration Sues Drug Company Over HIV Prevention Drug Truvada

A woman living in Marin County died from complications related to vaping, the county’s health officer said Wednesday — the first such death in the Bay Area and the fourth in California since July.

The Trump administration on Wednesday sued the drug manufacturer Gilead Sciences, which sells a landmark HIV drug touted as one of the most important mechanisms to stop the spread of the virus across the nation.

The U.S. government, on behalf of the Department of Health and Human Services, filed a lawsuit alleging Gilead, which makes the pre-exposure prophylaxis (PrEP) drug Truvada, had infringed on patents owned by the federal government.

Read Full Article

5/16/19: A Leading HIV Drug Is Way Overpriced in the U.S.

Gilead Sciences Inc. CEO Daniel O’Day has only been on the job since March, and he’s already found himself having to defend his company in front of the House Oversight and Reform committee.

O’Day faced questioning at a Thursday hearing over the high price of Truvada, a medicine approved to treat HIV and prevent infection. Activists claim that the price prevents at-risk people from accessing the drug and has helped keep infection rates high.

Read Full Article

5/9/19: Gilead Will Donate Truvada to U.S. for H.I.V. Prevention

The manufacturer will provide enough of the drug to supply 200,000 patients annually for more than a decade. Critics said it would not be enough to end the AIDS epidemic and questioned the company’s motives.

Read Full Article

2/15/19: Truvada TDF Litigation Document

 

When HIV/AIDS first hit, panic ensued as it was first considered a death sentence. The pharmaceutical industry was racing to find a treatment or a cure. TDF (later Viread, Truvada, and other names) entered the market and gave hopes of a potential miracle drug, rendering HIV a chronic disease. However, it caused kidney failure and bone deterioration. It seemed that patients were left with a choice – either death by AIDS or kidney failure and bone loss.  Little did they know that Gilead, the manufacturer of Truvada and other such drugs, had a safer, more effective alternative design in their back pocket – TAF. They sat on this alternative in silence for over a decade and moved forward with TDF drugs in order to maximize the profit from its first patent with TDF.

Download Now

 

GET YOUR FREE TRUVADA CASE REVIEW TODAY

Truvada cases are now being reviewed, but there is a limited window to pursue help. If you think you, a friend, or a family member may qualify, get your free case review today… before it’s too late!

  • * Submit now to learn if you may be eligible for a cash settlement or call (800) 511-3838 now.

Free Guide Download

The Step-By-Step Guide To Taking Action

How to File for Financial Settlement After Injury from an Unsafe Drug or Device

Free Guide Download

The Step-By-Step Guide To Taking Action

How to File for Financial Settlement After Injury from an Unsafe Drug or Device

LATEST ARTICLES

Periscope Group is not owned by or operated on behalf of any attorney or law firm. We are not affiliated with any drug or medical device companies. We do not host advertisements nor do we accept advertising requests. We are here to help YOU, the consumer, become better educated and supported. You pay absolutely nothing for our help. It’s as simple as that.

Periscope Group is not owned by or operated on behalf of any attorney or law firm. We are not affiliated with any drug or medical device companies. We do not host advertisements nor do we accept advertising requests. We are here to help YOU, the consumer, become better educated and supported. You pay absolutely nothing for our help. It’s as simple as that.

HON Code Certification

© All Rights Reserved • 2019 • Periscope Group, 4155 Blackhawk Plaza Circle, Suite 100, Danville, CA 94506 Legal Disclaimer

Protected by Copyscape

© All Rights Reserved • 2019 • Periscope Group, 4155 Blackhawk Plaza Circle, Suite 100, Danville, CA 94506 Legal Disclaimer

HON Code Certification

Pin It on Pinterest